What is LGND stock price today?

LGND (Ligand Pharmaceuticals Inc) stock is trading at $231.82 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is LGND stock going up or down today?

LGND stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy LGND stock now?

The decision to buy LGND depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is LGND a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for LGND based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is LGND stock overvalued or undervalued?

LGND currently trades at a P/E ratio of 37.82, which may indicate premium valuation. Our DCF calculator provides intrinsic value estimates to help determine if LGND is fairly priced.

What is LGND's P/E ratio?

LGND has a price-to-earnings (P/E) ratio of 37.82, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is LGND's market cap?

LGND (Ligand Pharmaceuticals Inc) has a market capitalization of $4.62 billion, making it a small-cap stock.

What is LGND's price to book ratio?

LGND trades at a price-to-book (P/B) ratio of 4.38, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does LGND pay dividends?

LGND does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is LGND's dividend yield?

LGND does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is LGND stock a good long-term investment?

LGND's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is LGND's revenue growth rate?

LGND has shown revenue growth of 0.4% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, LGND is profitable with a profit margin of 0.5%. This indicates the company generates 0.5 cents of profit for every dollar of revenue.

What are the risks of investing in LGND?

Key risks for LGND include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does LGND compare to its competitors?

Compare LGND to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize LGND's performance and positioning.

What is LGND's stock price target for 2026?

Our AI model provides price targets for LGND based on fundamental analysis: Bull case $301.37 (+30%), Base case $266.59 (+15%), Bear case $208.64 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about LGND?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for LGND. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is LGND's next earnings report?

LGND reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

LGND - Ligand Pharmaceuticals Inc

NYSE * Health Care * Biotechnology

$231.82

+$8.58 (+3.84%)

About Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

LGND Key Statistics

Market Cap

$4.62B

P/E Ratio

37.82

P/B Ratio

4.38

EPS

$6.13

Revenue Growth

+0.4%

Profit Margin

0.5%

Employees

How LGND Compares to Peers

LGND trades at a premium valuation vs peers (highest P/E)

LGND has the highest profit margins in Biotechnology

LGND has the fastest revenue growth among competitors

P/E Rank

of 6

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
LGND(This stock)	$4.62B	37.8	0%	0.5%	-
AMGNAmgen Inc	$191.53B	24.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$170.84B	20.3	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$112.22B	28.8	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$79.35B	18.1	0%	0.3%	vs REGN
BIIBBiogen Inc	$26.03B	20.0	-0%	0.1%	vs BIIB

Ligand Pharmaceuticals Inc Company Information

Headquarters: California; U.S.A
Website: www.ligand.com
Sector: Health Care
Industry: Biotechnology

About Ligand Pharmaceuticals Inc

LGND Key Statistics

How LGND Compares to Peers

Ligand Pharmaceuticals Inc Company Information

Upcoming Events for LGND